Clinical trials: Otorhinolaryngologic Neoplasms
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Hepatic Artery Infusion Pump for NPC Liver Metastases
A retrospective clinical trial to study the safety and effectiveness of hepatic arterial infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the liver.
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Liver
- Trial name
- NCT03876574
- Testing
- DSA-guided implantation of hepatic artery infusion pump, Gemcitabine, Floxuridine
- Volunteers
- 16 people
- Sponsor
- Xiangya Hospital of Central South University
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and…
- Trial name
- NCT04129320
- Testing
- enoblituzumab, MGA012, MGD013
- Sponsor
- MacroGenics
Nasopharyngeal Carcinoma
Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma
The standard of care for locally advanced nasopharyngeal carcinoma is radical chemoradiation(CRT).Recent advances in radiation techniques and supportive measures resulted in improvemnent of locoregional control and quality of…
- Trial name
- NCT04898374
- Testing
- Gemcitabin/cisplatin
- Where
- Kuwait
- Volunteers
- 120 people
- Sponsor
- Kuwait Cancer Control Center
Nasopharyngeal Carcinoma
Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
A phase II, open label, single arm, single agent study using nivolumab in patients who failed 2 or more lines of previous chemotherapy for recurrent/metastatic NPC (At least 1 line should include platinum based chemotherapy)
- Trial name
- NCT03390738
- Testing
- Nivolumab
- Sponsor
- The University of Hong Kong
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma (NPC)
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
This study aims to explore the efficacy and safety of risk-adapted adjuvant therapy based on dynamic EBV-DNA changes and MRI in nasopharyngeal carcinoma patients.
- Trial name
- NCT07762976
- Testing
- Observation, Adjuvant therapy
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Adebrelimab and Chemoradiotherapy in High-risk LANPC
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
- Trial name
- NCT06349889
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of neoadjuvant GP chemotherapy plus adebrelimab versus neoadjuvant GP chemotherapy in treating high-risk locoregionally advanced nasopharyngeal carcinoma patients.
- Trial name
- NCT06455410
- Testing
- GP, Adebrelimab, concurrent chemoradiotherapy (CCRT)
- Where
- 12 sites in China
- Volunteers
- 216 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy
To evaluate the sensitivity and specificity of the combination of EBV and methylation marker genes in body fluids of both plasma and nasopharyngeal brush together for screening of early salvageable local residual and recurrent…
- Trial name
- NCT03379610
- Testing
- Nasopharngeal brush
- Volunteers
- 426 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma
Ovarian Function of Nasopharyngeal Carcinoma Women Survivors
This is an observational cohort study aimed to explore the fertility concerns, fertility preservation strategies, fertility status (pregnancy and Ovarian Failure) and birth outcome among young woman Nasopharyngeal carcinoma…
- Trial name
- NCT05183724
- Where
- China
- Volunteers
- 602 people
- Sponsor
- Sun Yat-sen University
Pain, Nasopharyngeal Carcinoma
Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients
The primary purpose of this study is to explore the significance of analgesic treatment for radiation-induced oral mucositis pain in patients with nasopharyngeal carcinoma during radiotherapy, and to compare the analgesic effect…
- Conditions
- Pain, Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiation Induced Oral Mucositis
- Trial name
- NCT04292990
- Testing
- Fentanyl, Morphine
- Volunteers
- 300 people
- Sponsor
- Jiarong Chen, MD
Nasopharyngeal Carcinoma
The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients
An additional blood test at 2-3 months after RT is a valuable biomarker in predicting treatment outcome for NPC patients. Patients with persistently detectable EBV DNA during re-staging survey 2-3 months after RT should…
- Trial name
- NCT03981224
- Volunteers
- 706 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Laryngeal Neoplasms, Head and Neck Cancers
MRI Laryngeal Imaging With a Surface Coil
To determine if high resolution MRI can detect early invasion of cartilage by laryngeal carcinoma, and to determine if high resolution MRI may be superior to conventional MRI imaging or CT imaging to detect cartilage invasion.
- Conditions
- Laryngeal Neoplasms, Head and Neck Cancers, Larynx Cancer
- Trial name
- NCT00965003
- Testing
- MRI scan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Nasopharyngeal Carcinoma
EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients
EUS-FNA for RPLN in NPC
- Trial name
- NCT03006588
- Testing
- EUS-FNA for RPLN in NPC patients
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma
The investigators aim to evaluate the survival benefit from triple combination of induction, concurrent and aduvant chemotherapy versus concurrent chemotherapy alone for high risk locoregionally advanced nasopharyngeal carcinoma…
- Trial name
- NCT02621970
- Testing
- Cisplatin 1, Cisplatin 2, Docetaxel
- Where
- China
- Volunteers
- 534 people
- Sponsor
- Sun Yat-sen University
Oral Cavity Cancer, Oropharyngeal Cancer
Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients
This four-year, prospective, longitudinal study will evaluate and validate a patient-reported outcome measure, clinician-reported outcome measures, and imaging techniques in assessing characteristics, trajectory, and progression…
- Conditions
- Oral Cavity Cancer, Oropharyngeal Cancer, Lymphedema, Fibrosis
- Trial name
- NCT02412241
- Testing
- LEF measures, Technical measure
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Neurofibromatosis Type 2, Vestibular Schwannomas
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry.
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannomas, Meningiomas
- Trial name
- NCT01880749
- Testing
- RAD001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Head and Neck Cancer
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical research study is to learn if the addition of OSI-906 to cetuximab can improve response. The safety of these drugs will also be studied.
- Trial name
- NCT01427205
- Testing
- Cetuximab, OSI-906
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable.
- Trial name
- NCT01392235
- Testing
- Famitinib
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison